TY - JOUR
T1 - Genetic Burden of TNNI3K in Diagnostic Testing of Patients With Dilated Cardiomyopathy and Supraventricular Arrhythmias
AU - Pham, Caroline
AU - Andrzejczyk, Karolina
AU - Jurgens, Sean J.
AU - Lekanne Deprez, Ronald
AU - Palm, Kaylin C. A.
AU - Vermeer, Alexa M. C.
AU - Nijman, Janneke
AU - Christiaans, Imke
AU - Barge-Schaapveld, Daniela Q. C. M.
AU - van Dessel, Pascal F. H. M.
AU - Beekman, Leander
AU - Choi, Seung Hoan
AU - Lubitz, Steven A.
AU - Skoric-Milosavljevic, Doris
AU - van den Bersselaar, Lisa
AU - Jansen, Philip R.
AU - Copier, Jaël S.
AU - Ellinor, Patrick T.
AU - Wilde, Arthur A. M.
AU - Bezzina, Connie R.
AU - Lodder, Elisabeth M.
N1 - Funding Information: This research was funded by the Netherlands CardioVascular Research Initiative: CVON2017-15 RESCUED, the Dutch Research Council: NWO Talent Scheme VIDI-91718361 (Drs Lodder, K. Andrzejczyk, and C. Pham), and the AMC funding scheme (J.S. Copier and Dr Lodder). S.J. Jurgens is supported by a Junior Clinical Scientist Fellowship (03-007-2022-0035) from the Dutch Heart Foundation, and by an Amsterdam UMC Doctoral Fellowship (Hartstichting). Dr Ellinor is supported by grants from the National Institutes of Health (1RO1HL092577, 1R01HL157635, 1R01HL157635), by a grant from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and by a grant from the European Union (MAESTRIA 965286). Dr Lubitz is a full-time employee of Novartis as of July 18, 2022. Prior to his employment at Novartis and during this work, he was supported by NIH grants R01HL139731, R01HL157635 and American Heart Association 18SFRN34250007. Publisher Copyright: © 2021 Society of Trauma Nurses. Unauthorized reproduction of this article is prohibited.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - BACKGROUND: Genetic variants in TNNI3K (troponin-I interacting kinase) have previously been associated with dilated cardiomyopathy (DCM), cardiac conduction disease, and supraventricular tachycardias. However, the link between TNNI3K variants and these cardiac phenotypes shows a lack of consensus concerning phenotype and protein function. METHODS: We describe a systematic retrospective study of a cohort of patients undergoing genetic testing for cardiac arrhythmias and cardiomyopathy including TNNI3K. We further performed burden testing of TNNI3K in the UK Biobank. For 2 novel TNNI3K variants, we tested cosegregation. TNNI3K kinase function was estimated by TNNI3K autophosphorylation assays. RESULTS: We demonstrate enrichment of rare coding TNNI3K variants in DCM patients in the Amsterdam cohort. In the UK Biobank, we observed an association between TNNI3K missense (but not loss-of-function) variants and DCM and atrial fibrillation. Furthermore, we demonstrate genetic segregation for 2 rare variants, TNNI3K-p.Ile512Thr and TNNI3K-p.His592Tyr, with phenotypes consisting of DCM, cardiac conduction disease, and supraventricular tachycardia, together with increased autophosphorylation. In contrast, TNNI3K-p.Arg556_Asn590del, a likely benign variant, demonstrated depleted autophosphorylation. CONCLUSIONS: Our findings demonstrate an increased burden of rare coding TNNI3K variants in cardiac patients with DCM. Furthermore, we present 2 novel likely pathogenic TNNI3K variants with increased autophosphorylation, suggesting that enhanced autophosphorylation is likely to drive pathogenicity.
AB - BACKGROUND: Genetic variants in TNNI3K (troponin-I interacting kinase) have previously been associated with dilated cardiomyopathy (DCM), cardiac conduction disease, and supraventricular tachycardias. However, the link between TNNI3K variants and these cardiac phenotypes shows a lack of consensus concerning phenotype and protein function. METHODS: We describe a systematic retrospective study of a cohort of patients undergoing genetic testing for cardiac arrhythmias and cardiomyopathy including TNNI3K. We further performed burden testing of TNNI3K in the UK Biobank. For 2 novel TNNI3K variants, we tested cosegregation. TNNI3K kinase function was estimated by TNNI3K autophosphorylation assays. RESULTS: We demonstrate enrichment of rare coding TNNI3K variants in DCM patients in the Amsterdam cohort. In the UK Biobank, we observed an association between TNNI3K missense (but not loss-of-function) variants and DCM and atrial fibrillation. Furthermore, we demonstrate genetic segregation for 2 rare variants, TNNI3K-p.Ile512Thr and TNNI3K-p.His592Tyr, with phenotypes consisting of DCM, cardiac conduction disease, and supraventricular tachycardia, together with increased autophosphorylation. In contrast, TNNI3K-p.Arg556_Asn590del, a likely benign variant, demonstrated depleted autophosphorylation. CONCLUSIONS: Our findings demonstrate an increased burden of rare coding TNNI3K variants in cardiac patients with DCM. Furthermore, we present 2 novel likely pathogenic TNNI3K variants with increased autophosphorylation, suggesting that enhanced autophosphorylation is likely to drive pathogenicity.
KW - cardiac arrhythmias
KW - dilated cardiomyopathy
KW - genetics
KW - phosphorylation
UR - http://www.scopus.com/inward/record.url?scp=85168222844&partnerID=8YFLogxK
U2 - https://doi.org/10.1161/CIRCGEN.122.003975
DO - https://doi.org/10.1161/CIRCGEN.122.003975
M3 - Article
C2 - 37199186
SN - 2574-8300
VL - 16
SP - 328
EP - 336
JO - Circulation. Genomic and precision medicine
JF - Circulation. Genomic and precision medicine
IS - 4
ER -